La Jolla Pharmaceutical Co

La Jolla Pharmaceutical — Investor Presentation (September 2016)

34 slides from La Jolla Pharmaceutical's investor presentation, Sep 19, 2016

  1. Slide 1: Corporate Presentation

    September 2016 Developing Innovative Therapies for Patients Suffering from Life-threatening Diseases NASDAQ: LJPC Corporate Presentation

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements These slides contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking terminology such as "anticipate", "believe", "continue", "could", "estimate", "exp

  3. Slide 3: Agenda

    • Overview of LJPC • LJPC-501 (Angiotensin II) for CRH • LJPC-401 (Synthetic Hepcidin) for Iron Overload • LJPC-30S (Gentamicin Derivative) for Bacterial Infections and Rare Genetic Diseases • Financial Position Agenda 3

  4. Slide 4: Mission Statement

    Mission Statement La Jolla is dedicated to improving the lives of patients suffering from life- threatening diseases by discovering and developing innovative therapies 4

  5. Slide 5: LJPC Corporate Highlights

    LJPC Corporate Highlights • Focused on de-risked product opportunities  Naturally occurring peptides with well-understood biological functions  Derivative components of FDA-approved products • LJPC-501 (angiotensin II) for catecholamine-resistant hypotension (CRH)  Phase 3 registration study (und

  6. Slide 6: Product Pipeline

    Product Pipeline Underway Completed Planned 6 LJPC-501 Angiotensin II LJPC-401 Synthetic Hepcidin Other R&D Indication IND Phase 1 Phase 2 Phase 3 CRH Sept. 2016 Various Q1 2017 HH, Thalassemia, SCD and MDS Q4 2015 LJPC-30S Gentamicin Derivative Bacterial Infections/Rare Genetic Diseases Q1 2015 Suc

  7. Slide 7: Agenda

    • Overview of LJPC • LJPC-501 (Angiotensin II) for CRH • LJPC-401 (Synthetic Hepcidin) for Iron Overload • LJPC-30S (Gentamicin Derivative) for Bacterial Infections and Rare Genetic Diseases • Financial Position Agenda 7

  8. Slide 8: LJPC-501: Overview

    LJPC-501: Overview 8 • LJPC-501 is a proprietary formulation of angiotensin II, a naturally occurring regulator of blood pressure • Catecholamine-resistant hypotension (CRH) is an acute, life-threatening condition in which blood pressure drops to dangerously low levels and is unresponsive to current

  9. Slide 9: Three Systems Work in Harmony to Regulate Blood Pressure

    Three Systems Work in Harmony to Regulate Blood Pressure 9 Current therapeutic options for the treatment of acute hypotension only leverage the adrenal system and vasopressin system The Body’s Three Systems that Regulate Blood Pressure

  10. Slide 10: High Doses of Catecholamines Increase Mortality

    High Doses of Catecholamines Increase Mortality 10 Sources: Sviri et al, J. of Crit Care, 29;157-160, 2014 and Morelli et al, JAMA Oct23/30, 310:1683-1691, 2013 • Catecholamines (i.e., norepinephrine, epinephrine and dopamine) cause cardiac toxicity, digital necrosis and metabolic complications lead

  11. Slide 11: Norepinephrine Dose Decreases with Angiotensin II

    Norepinephrine Dose Decreases with Angiotensin II Surrogate Effect on Blood Pressure 11 Source: Chawla et al, Critical Care, 18:534, 2014 • Randomized, placebo-controlled, double-blind pilot trial • Primary efficacy endpoint:  Catecholamine dose sparing; surrogate for BP effect • Published October

  12. Slide 12: LJPC-501: Phase 3 Trial in CRH

    LJPC-501: Phase 3 Trial in CRH SPA Agreement with FDA Reached, Trial Enrolling 12 • ATHOS (Angiotensin II for the Treatment of High-Output Shock) 3 trial initiated in March 2015 • Randomized, placebo-controlled, double-blind Phase 3 trial • Patient population: catecholamine-resistant, based on amoun

  13. Slide 13: U.S. Acute Hypotension Patient Population and Treatment Paradigm

    U.S. Acute Hypotension Patient Population and Treatment Paradigm 13 18.84MM annualized vials (737K vials sold in July 2016 X 12); Symphony Health Solutions, 2016. 97% of vials sold for hypotensive shock; estimate based on medical literature. 13 vials used per patient; estimate based on Russell et al

  14. Slide 14: LJPC-501: Summary

    LJPC-501: Summary 14 • LJPC-501 is a proprietary formulation of angiotensin II, a naturally occurring regulator of blood pressure • Catecholamine-resistant hypotension (CRH) is an acute, life-threatening condition in which blood pressure drops to dangerously low levels and is unresponsive to current

  15. Slide 15: Agenda

    • Overview of LJPC • LJPC-501 (Angiotensin II) for CRH • LJPC-401 (Synthetic Hepcidin) for Iron Overload • LJPC-30S (Gentamicin Derivative) for Bacterial Infections and Rare Genetic Diseases • Financial Position Agenda 15

  16. Slide 16: LJPC-401: Overview

    LJPC-401: Overview • LJPC-401 is a novel formulation of synthetic hepcidin, a naturally occurring regulator of iron absorption and distribution • Primary iron overload  Hereditary hemochromatosis (HH) is characterized by a genetic deficiency of hepcidin resulting in excessive iron accumulation – Mo

  17. Slide 17: Hepcidin: The Insulin of Iron Metabolism

    Hepcidin: The Insulin of Iron Metabolism • Hepcidin: the insulin of iron metabolism  Regulates iron absorption and disposition in all organs  Rapid and sustained lowering of iron levels • Progress  SC formulation developed  Orphan Drug Designation granted (EU)  Positive Phase 1 study results 

  18. Slide 18: LJPC-401: Phase 1 Study Design

    PRIMARY ENDPOINT Safety and tolerability via review of: Treatment Emergent Adverse Events (TEAEs), changes in clinical lab values, ECGs, vital sign and physical exam data SECONDARY ENDPOINT Serum iron LJPC-401: Phase 1 Study Design • Population: Adult patients at risk of iron overload (e.g., HH, tha

  19. Slide 19: LJPC-401: Phase 1 Results Overview

    LJPC-401: Phase 1 Results Overview • Fifteen patients dosed at escalating dose levels from 1 mg to 20 mg  Patient subtypes treated: HH = 10; SCD = 3; and thalassemia = 2 • Safety observations  No dose-limiting toxicities at any dose level  1 SAE at 1 mg dose level unrelated to study drug – Hospit

  20. Slide 20: LJPC-401: Percent Change in Serum Iron, Baseline to Hour 8

    Dose Response p=0.008 Individual dose p-values for change from baseline not adjusted for a potential regression to the mean effect. Dose response not adjusted for multiple comparisons. LJPC-401: Percent Change in Serum Iron Baseline to Hour 8 20

  21. Slide 21: LJPC-401: Percent Change in Serum Iron Through Day 7

    Nominal Time from Treatment (hours) Pe rce nt C ha ng e fro m Ba se lin e (% ) 0 8 24 48 168 -100 -75 -50 -25 0 25 Serum Iron: Percent Change from Baseline Change from baseline through day 7: -21% LJPC-401: Percent Change in Serum Iron Baseline through Day 7 for 20 mg Dose 21

  22. Slide 22: LJPC-401: Phase 1 Results Summary

    LJPC-401: Phase 1 Results Summary • Fifteen patients received a single dose ranging from 1 mg to 20 mg  Patient subtypes treated: HH = 10; SCD = 3; and thalassemia = 2 • Well tolerated with no dose-limiting toxicities  Mild to moderate, transient and self-limiting injection-site reactions • Profou

  23. Slide 23: LJPC-401: Update on Registration Plan

    • Agreement reached with European Medicines Agency (EMA) on pivotal study design • Randomized, controlled, multi-center study in beta thalassemia patients suffering from iron overload  A major unmet medical need in an orphan patient population • Primary endpoint is a clinically relevant measurement

  24. Slide 24: LJPC-401: Patient Need

    LJPC-401: Patient Need • Hereditary Hemochromatosis (HH)  Most common genetic disease in Caucasians  Silent Killer - Iron accumulation can lead to liver cirrhosis, liver cancer, heart disease and/or failure, and diabetes  No FDA-approved treatment  Current treatments don’t address the underlying

  25. Slide 25: Agenda

    • Overview of LJPC • LJPC-501 (Angiotensin II) for CRH • LJPC-401 (Synthetic Hepcidin) for Iron Overload • LJPC-30S (Gentamicin Derivative) for Bacterial Infections and Rare Genetic Diseases • Financial Position Agenda 25

  26. Slide 26: LJPC-30S: Overview

    LJPC-30S: Overview • LJPC-30S is a purified derivative of gentamicin, which retains biologic activity but lacks traditional kidney toxicity • Gentamicin: FDA-approved, standard-of-care for serious Gram-negative bacterial infections  Mixture of several distinct but closely related chemical entities

  27. Slide 27: LJPC-30S: Potential for Improved Clinical Profile

    Next-generation improved gentamicin derivative 1. Retain activity LJPC-30S: Potential for Improved Clinical Profile 27 2. Improve safety 0.0 4.0 8.0 12.0 16.0 placebo next-generation gentamicin derivative gentamicin In h ibi tio n /k ill z o n e ( m m ) B.subtilus K.pneumonieae (kill) K.pneumonieae

  28. Slide 28: LJPC-30S: Mechanism of Action

    Gentamicin induces errors in the translation of genes into proteins Bacteria LJPC-30S: Mechanism of Action Can Be Leveraged Toward Two Therapeutic Opportunities 28 Alters protein synthesis leading to cell death Alters protein synthesis to allow read through of stop-codon mutations Humans

  29. Slide 29: LJPC-30S: Clinical Proof-of-Concept in Cystic Fibrosis

    LJPC-30S: Clinical Proof-of-Concept in Cystic Fibrosis 29 Sources: Sermet-Gaudelus et al, BMC Medicine, 5:5, 2007; Wilchanski et al, NEJM, 349:1433-41, 2003 and Clancy J.P. et al, Am J Respir Crit Care Med, 163:1683-1692, 2001 • Three, independent studies suggest gentamicin helps read through stop-c

  30. Slide 30: LJPC-30S: Current Antibiotic Usage

    LJPC-30S: Current Antibiotic Usage • Antibiotic opportunity = $500+ million per year in U.S.1  Market could expand with a safer alternative – Increased duration of therapy, increased penetration, and/or new indications • Other large potential market opportunity in rare genetic diseases, such as cys

  31. Slide 31: Agenda

    • Overview of LJPC • LJPC-501 (Angiotensin II) for CRH • LJPC-401 (Synthetic Hepcidin) for Iron Overload • LJPC-30S (Gentamicin Derivative) for Bacterial Infections and Rare Genetic Diseases • Financial Position Agenda 31

  32. Slide 32: Financial Position

    Financial Position 32 Condensed Balance Sheet Data As of June 30, 2016 (in millions) Cash $100.6 Total liabilities $5.2 Total shareholders’ equity $99.6 Fully Diluted, As-Converted Shares Outstanding* 28,307,476 *Includes common stock, preferred stock (as-converted) & outstanding equity awards as of

  33. Slide 33: LJPC Corporate Highlights

    LJPC Corporate Highlights • Focused on de-risked product opportunities  Naturally occurring peptides with well-understood biological functions  Derivative components of FDA-approved products • LJPC-501 (angiotensin II) for catecholamine-resistant hypotension (CRH)  Phase 3 registration study (und

  34. Slide 34: @Lavolla

    he @Lavolla

LA Jolla Pharmaceutical — Investor Presentation (September 2016) on 6ix